Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for improving balance and gait deficits and reducing the risk of falling, today announced the establishment of Revelation Neuro, Inc. (“Revelation Neuro”), its wholly-owned private subsidiary focused on the development of non-implantable AI powered BCI technology.
“We are thrilled to establish Revelation Neuro to pursue the development of a new gold standard of care for personalized neurorehabilitation using a non-implantable AI powered BCI combining our newly developed intellectual property (“IP”) with Helius’ existing IP. Our technology relies on its proven ability to modulate known target brain processes and trigger therapeutic responses by using translingual stimulation without risky implantation. We believe Revelation Neuro’s BCI technology will be a unique and less invasive therapeutic option,” said Dane Andreeff, Helius President and Chief Executive Officer.
“Revelation Neuro is focused on maximizing the positive effect of neuromodulation by applying AI to optimize individual response to translingual stimulation,” Andreeff continued. “Helius’ extensive dataset, comprised of more than 5 years of movement dysfunction clinical evidence from over 400 subjects, will serve as the initial foundation for AI algorithm development to which new patient data will then be added to optimize the algorithm and enable a precise and personalized approach to motor function rehabilitation. Revolutionary BCI-enabled improvement in functional rehabilitation is the initial focus of Revelation Neuro’s efforts, with the potential in the future to address neurological conditions including cognitive deficit, mood and behavior disorders.”
Revelation Neuro is a private subsidiary 100% owned by Helius Medical Technologies, Inc. Helius intends to assign its newly developed IP and to license its existing IP to Revelation Neuro. Leveraging over $70 million invested to date in the development of a novel and proprietary neuromodulation mechanism of action and data gathering will allow expedited development of Revelation Neuro’s AI powered BCI. Helius does not intend to invest significant additional capital in the wholly owned subsidiary but instead expects it to be financed through third-party outside sources.
